Small molecule · Activator of mTORC1 · developed by Supernus Pharmaceuticals
SPN-821 is an orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling. It is being studied in major depressive disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07226661 | Phase 2 | Major Depressive Disorder (MDD) | Recruiting | SUPN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Major Depressive Disorder (MDD)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.
See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SUPN catalysts and pipeline →